US-based Continuus Pharmaceuticals has opened a new laboratory space and new technology to help the development of high-potency drugs.
The new lab and technology are the latest developments in Continuus’ ongoing expansion, coming six months after receiving a US$69.3 million US government contract for the domestic production of medicines.
“Our new lab space, located one mile from our current manufacturing site and corporate headquarters, will help Continuus advance our mission for on-demand delivery of affordable, high-quality, vital medicines to patients in need of therapeutic solutions, and will also help facilitate collaborations with innovator companies that are developing high-potency drugs,” said Salvatore Mascia, Founder and Chief Executive officer of Continuus.
